Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PT
Pelthos Therapeutics Inc.
PTHS
Mkt Cap
$77.4M
Volume
72.62K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PT
PTHS
PT
Pelthos Therapeutics Inc.
PTHS
News
·
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Mkt Cap
$77.6M
Volume
72.62K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Pelthos Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 29, 2026. The meeting date represents a change of more than 30 days from the 2025 Annual Meeting anniversary, with stockholder proposals due by August 3, 2026. The company is a commercial-stage biopharmaceutical firm focused on cutaneous infectious disease products.
GlobeNewswire Inc. · Jul 24, 2026
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will present at the Jefferies Global Healthcare Conference on June 4, 2026, and participate in one-on-one investor meetings. The company's lead product ZELSUVMI (berdazimer) showed 17% quarter-over-quarter revenue growth, reaching $10.7 million in Q1 2026.
GlobeNewswire Inc. · May 28, 2026
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
Pelthos Therapeutics Inc. (PTHS) announced the acquisition of Xeglyze® (abametapir), an FDA-approved topical treatment for head lice, from Australian biotech company Hatchtech Pty Ltd. for $1.8 million. The acquisition adds a complementary product to Pelthos' portfolio with no future milestone or royalty payments owed. The company plans to relaunch Xeglyze in the first half of 2027, leveraging its existing commercial infrastructure.
Benzinga · Jan 5, 2026
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Pelthos Therapeutics Inc. (NYSE American: PTHS) announced the appointment of veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Einhorn brings over four decades of experience in investment banking, capital markets, and C-level finance roles at life science companies. He will serve on the Audit Committee and Compensation Committee. The appointment increases the Pelthos Board to eight directors.
GlobeNewswire Inc. · Dec 23, 2025
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.
GlobeNewswire Inc. · Dec 9, 2025
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to expand patient access to ZELSUVMI, its FDA-approved topical gel for treating molluscum contagiosum, which affects an estimated 16.7 million people annually.
GlobeNewswire Inc. · Dec 4, 2025
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
Pelthos Therapeutics will hold a conference call on November 13, 2025, at 8:00 a.m. Eastern Time to discuss its third quarter financial results for the period ended September 30, 2025.
GlobeNewswire Inc. · Nov 5, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PT
PTHS
Pelthos Therapeutics Inc.
Buy
Sell
Market
Limit
Soon
PTHS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PTHS yet.
Related Tickers
Earnings